Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival Source: Eur Respir J 2009; 33: 118-126 Year: 2009
Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010
The prognostic influence of tumor infiltrating M1 and M2 phenotype macrophages in resected non-small cell lung cancer Source: International Congress 2016 – Lung cancer immunology: latest research Year: 2016
LSC Abstract – Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features Source: International Congress 2016 – Lung cancer immunology: latest research Year: 2016
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002
LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Heterogeneous reactivity of ICAM-1 on alveolar macrophages (AMs) in patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 256s Year: 2003
Cytotoxicity and apotosis of alveolar lymphocytes (AL) in early clinical stage (I-IIa) of non-small cell lung cancer (NSCLC) Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Humanized S.typhi flagellin (FliC) transfected non-small cell lung cancer (NSCLC) cells induce local inflammatory and necrotic changes in an experimental model Source: Annual Congress 2011 - Phagocytes and dendritic cells Year: 2011
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer Source: Eur Respir J , 49 (4) 1600711; DOI: 10.1183/13993003.00711-2016 Year: 2017
Differences of the hypoxia driven gene response in small (H69) and nonsmall (H23) cell lung carcinomas Source: Eur Respir J 2001; 18: Suppl. 33, 16s Year: 2001
KPNB1-mediated PD-L1 nuclear translocation promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signalling pathway Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
NEUROD1 is highly expressed in extensive disease small cell lung cancer by promoting migration. Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
A low endothelial cell proliferation fraction, a measurement of ongoing angiogenesis, is associated with poor prognosis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 763s Year: 2006
Investigation of a relationship between NF-KB1A gene polymorphism and non small cell lung cancer (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006